162 related articles for article (PubMed ID: 19759813)
1. A simple approach discriminating cardio-safe drugs from toxic ones.
Falah M; Nassar T; Rayan A
Bioinformation; 2009 Jun; 3(9):389-93. PubMed ID: 19759813
[TBL] [Abstract][Full Text] [Related]
2. Indexing molecules for their hERG liability.
Rayan A; Falah M; Raiyn J; Da'adoosh B; Kadan S; Zaid H; Goldblum A
Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540
[TBL] [Abstract][Full Text] [Related]
3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
4. QT prolongation and safety in the Indian population.
Dabhi J; Mehta A
Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
[TBL] [Abstract][Full Text] [Related]
5. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
[TBL] [Abstract][Full Text] [Related]
6. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy.
Roden DM
Cardiovasc Res; 2019 Apr; 115(5):895-903. PubMed ID: 30689740
[TBL] [Abstract][Full Text] [Related]
7. Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins.
Dumotier BM; Georgieva AV
Cell Biol Toxicol; 2007 Jul; 23(4):293-302. PubMed ID: 17216548
[TBL] [Abstract][Full Text] [Related]
8. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced life-threatening arrhythmias and sudden cardiac death: A clinical perspective of long QT, short QT and Brugada syndromes.
Ramalho D; Freitas J
Rev Port Cardiol (Engl Ed); 2018 May; 37(5):435-446. PubMed ID: 29636202
[TBL] [Abstract][Full Text] [Related]
10. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology.
Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C
Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421
[TBL] [Abstract][Full Text] [Related]
11. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.
Cavero I; Mestre M; Guillon JM; Crumb W
Expert Opin Pharmacother; 2000 Jul; 1(5):947-73. PubMed ID: 11249502
[TBL] [Abstract][Full Text] [Related]
12. A simple model to solve a complex drug toxicity problem.
Dixit VA
Toxicol Res (Camb); 2019 Mar; 8(2):157-171. PubMed ID: 30997019
[TBL] [Abstract][Full Text] [Related]
13. The impact of drug-induced QT interval prolongation on drug discovery and development.
Fermini B; Fossa AA
Nat Rev Drug Discov; 2003 Jun; 2(6):439-47. PubMed ID: 12776219
[TBL] [Abstract][Full Text] [Related]
14. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
Gwathmey JK; Tsaioun K; Hajjar RJ
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic drugs and QT interval prolongation.
Zareba W; Lin DA
Psychiatr Q; 2003; 74(3):291-306. PubMed ID: 12918603
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
17. Screening for QT Prolongation in the Emergency Department: Is There a Better "Rule of Thumb?".
Rischall ML; Smith SW; Friedman AB
West J Emerg Med; 2020 Feb; 21(2):226-232. PubMed ID: 32191180
[TBL] [Abstract][Full Text] [Related]
18. Food and Drug Administration Beyond the 2001 Government Accountability Office Report: Promoting Drug Safety for Women.
Jenkins MR; Munoz MA; Bak D; Chai G; Ready T; South EM; Zinn RL; Zusterzeel R; Woodcock J
J Womens Health (Larchmt); 2021 Jul; 30(7):927-934. PubMed ID: 33635140
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Index of Cardio-Electrophysiological Balance (iCEB) as a New Biomarker for the Identification of Patients at Increased Arrhythmic Risk.
Robyns T; Lu HR; Gallacher DJ; Garweg C; Ector J; Willems R; Janssens S; Nuyens D
Ann Noninvasive Electrocardiol; 2016 May; 21(3):294-304. PubMed ID: 26305685
[TBL] [Abstract][Full Text] [Related]
20. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
